Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 6 Issue 1

The Hepatitis B with Delta Agent Problems of Therapy

ST Tobokalova1*, KA Nogoybaeva1 and JT Aitieva2

1Kyrgyz State Medical Institute of Postgraduate Education N. S.B. Daniarov, Bishkek, Kyrgyz Republic
2Osh State university, Osh, Kyrgyz Republic

*Corresponding Author: ST Tobokalova, Kyrgyz State Medical Institute of Postgraduate Education N. S.B. Daniarov, Bishkek, Kyrgyz Republic.

Received: May 31, 2021; Published: July 19, 2021


  Thus, to date, the only approved etiotropic drug for viral hepatitis D is - peg IFN, which is combined with nucleoside analogues in the presence of an HBV viral load. According to systematic data for example, the use of humanized mice as a laboratory model made it possible to better understand the issues of hepatitis virus replication and integration D with host cells. As a result, researchers have developed several antiviral drugs aimed at different parts of the pathogenesis of HDV infection. Prenylation inhibitor-Lonafarnib, which blocks the exit of HDV particles from the cell; nucleic acid polymers (NAP) (REP2139Ca), an oligopeptide that mainly affects the penetration of the virus into the cell, and Myrcludex B- lipopeptide, preventing the formation of HDV RNA in initialized hepatocytes, undergoing various phases of testing in different countries.

Keywords: Hepatitis D Infection; Antiviral Therapy; Lonafarnib; Myrcludex B


  1. Patel EU., et al. “Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011‐2016”. Clinical Infectious Diseases 69 (2019): 709‐712.
  2. Romeo R., et al. “A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma”. Gastroenterology 136 (2009): 1629-1638.
  3. Vincent TL., et al. “Targeting the Host for New Therapeutic Perspectives in Hepatitis D”. Clinical Medicine 9 (2020): 1.
  4. Rizzetto M., et al. “Treatment of chronic delta hepatitis with α-2 recombinant interferon”. Journal of Hepatology 3 (1986): S229-S233.
  5. Wedemeyer H., et al. “Peginterferon plus adefovir versus either drug alone for hepatitis delta”. The New England Journal of Medicine 364 (2011): 322-331.
  6. Wranke A., et al. “Current management of HBV/HDV coinfection and future perspectives”. Current Hepatology Reports 14 (2015): 284-292.
  7. Zoulim F., et al. “Quantification of HbsAg in nucleos (t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the be-low study”. Journal of Hepatology 62 (2015): 56-63.
  8. Lampertico P., et al. “EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection”. Journal of Hepatology (2017).
  9. Soriano V., et al. “Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients”. AIDS 28 (2014): 2389-2394.
  10. Wedemeyer H., et al. “Peginterferon plus adefovir versus either drug alone for hepatitis delta”. The New England Journal of Medicine 364 (2011): 322-331.
  11. Wedemeyer H., et al. “O4 prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2A plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: The HIDIT-2 study”. Journal of Hepatology 60 (2014): S2-S3.
  12. Florian A., et al. “Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen”. Viruses 7 (2017): 172.
  13. Koh C., et al. “Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2a trial”. Lancet Infectious Disease 15 (2015): 1167-1174.
  14. Rizzetto M and A Ciancio. “The prenylation inhibitor, lonafarnib: A new therapeutic strategy against hepatitis delta”. Lancet Infectious Disease 15 (2015): 1119-1120.
  15. Bordier BB., et al. “In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus”. Journal of Clinical Investigation 112 (2003): 407-414.
  16. Mijimolle N., et al. “Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development”. Cancer Cell 7 (2005): 313-324.
  17. Palsuledesai CC., et al. “Protein prenylation: Enzymes, therapeutics, and biotechnology applications”. ACS Chemical Biology 10 (2015): 51-62.
  18. Yurdaydin C. “Recent advances in managing hepatitis D. Version 1”. F1000 Research 6 (2017): 1596.
  19. Bazinet M., et al. “Hdv2 o-09: Rep 2139 monotherapy and combination therapy with pegylated interferon: Safety and potent reduction of HbsAg and HDV RNA in patients with chronic HBV/HDV co-infection”. Journal of Viral Hepatitis 22 (2015): 5-6.
  20. Noordeen F., et al. “Therapeutic antiviral effect of the nucleic acid polymer rep 2055 against persistent duck hepatitis B virus infection”. PloS ONE 10 (2015): e0140909.
  21. “Replicor” (2017).
  22. Schulze A., et al. “Fine mapping of pre-s sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction”. Journal of Virology 84 (2010): 1989-2000.
  23. Meier A., et al. “Myristoylated PRES1-domain of the hepatitis B virus l-protein mediates specific binding to differentiated hepatocytes”. Hepatology 58 (2013): 31-42.
  24. Lempp FA., et al. “Hepatitis delta virus: Insights into a peculiar pathogen and novel treatment options”. Nature Reviews Gastroenterology and Hepatology 13 (2016): 580-589.
  25. Nkongolo S., et al. “Cyclosporin a inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor”. Journal of Hepatology 60 (2014): 723-731.
  26. Haag M. “Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: Monitoring hepatitis B therapy by a novel Na (+)-taurocholate cotransporting polypeptide inhibitor”. Analytical and Bioanalytical Chemistry 407 (2015): 6815-6825.
  27. Slijepcevic D., et al. “Impaired uptake of conjugated bile acids and hepatitis B virus PRES1-binding in Na (+) -taurocholate cotransporting polypeptide knockout mice”. Hepatology 62 (2015): 207-219.
  28. Lin H., et al. “Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype”. Hepatology 61 (2015): 260-267.
  29. Deng M. “Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency”. Experimental and Therapeutic Medicine 12 (2016): 3294-3300.
  30. Blank A., et al. “First-in-human application of the first-in-class hepatitis B and hepatitis D virus entry inhibitor myrcludex B”. Journal of Hepatology 65 (2016): 483-489.
  31. Bogomolov P., et al. “A proof-of-concept phase 2a clinical trial with HBV/HDV entry inhibitor myrcludex b”. Hepatology 60 (2014): 1279A-1280A.
  32. Bogomolov P., et al. “Treatment of chronic hepatitis D with the entry inhibitor myrcludex b—First results of a phase Ib/Iia study”. Journal of Hepatology 65 (2016): 490-498.
  33. Elazar M and JS Glenn. “Emerging concepts for the treatment of hepatitis delta”. Current Opinion on Virology 24 (2017): 55-59.


Citation: ST Tobokalova., et al. “The Hepatitis B with Delta Agent Problems of Therapy”.Acta Scientific Medical Sciences 6.1 (2022): 78-84.


Copyright: © 2022 ST Tobokalova., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

Contact US